Olive is a private healthcare automation company that uses software and AI to reduce administrative work for hospitals, health systems, and payers. It was founded in 2012 and is based in Columbus, Ohio.
UpMarket does not offer Olive shares. This page covers Olive's history before its assets were sold to Waystar and Humata Health.
Status
Assets sold
To Waystar and Humata Health, Oct 2023
Last Private Valuation
Not confirmed
Not confirmed by two independent reputable sources
How to Review Olive's Funding History on UpMarket
Olive wound down its business and sold its technology and team to Waystar and Humata Health in October 2023. UpMarket does not offer Olive shares. This page covers Olive's earlier valuation and funding history.
Step 01
Check the transaction details
Olive sold its technology, patents and team to Waystar and Humata Health in October 2023.
Step 02
Review the valuation history
See how Olive's private-market valuation changed across funding rounds before the sale.
Step 03
Review funding and revenue data
See reported funding rounds and revenue figures on this page, with their sources.
Step 04
Explore private companies
Accredited investors can review UpMarket's current pre-IPO offerings in companies that have not yet gone public.
Pre-IPO investments are illiquid, speculative, and involve risk of total loss of capital.
${{aum_amount_brokered_en}}B+
UpMarket has brokered over ${{aum_amount_brokered_en}} billion in alternative investments*
*Includes principal invested and appreciation of investments originated via the UpMarket platform based on historical trade volume and valuation estimates through {{aum_as_of_date_en}}. Of the total, approximately ${{aum_amount_managed_en}} million is managed by UpMarket Management, with the remaining originated investments managed by affiliates. Past performance is not predictive of future results.
Valuation Growth Over Time
Post-money valuation by round
Previous roundsMost recent
Date
Round
PPS (split-adj.)
Valuation
Why Investors Are Watching Olive
Growth Signal
Olive raised $51M to scale AI workflow automation
Olive closed a $51 million round to scale its AI-enabled robotic process automation for healthcare operations. The round was led by General Catalyst, with Drive Capital, Oak HC/FT and Ascension Ventures also participating, bringing total funding to about $123.8 million.
Competitive Moat
General Catalyst said Olive is built exclusively for healthcare
General Catalyst described Olive as built specifically and exclusively for the healthcare industry, with an AI-as-a-Service model designed to work with popular health systems. That healthcare-only focus can create domain depth and implementation know-how that generic automation tools may lack.
Looking for companies that are still private? Browse UpMarket's pre-IPO company directory. Accredited investors only.
UpMarket curates and conducts independent diligence on every investment opportunity before it reaches the platform.
Strategy, fees & legal reviewed in full
We review every offering's strategy, risk management, liquidity, fees, valuation methodology, tax matters, and all third-party providers: legal counsel, auditor, administrator, and custodian.
Disciplined managers only
We offer investments exclusively from disciplined managers that pursue unique strategies across an array of asset classes.
Built around your objectives
Our goal is to empower you to build a portfolio that best meets your individual investment objectives.
No. Olive wound down its business and sold its technology, patents and team to Waystar and Humata Health in October 2023. Olive has no shares that trade, and UpMarket does not offer Olive shares.
Olive has no stock price. The prices shown on this page are historical private-market prices from before its assets were sold to Waystar and Humata Health.
No. Olive no longer operates as an independent company and UpMarket does not offer Olive shares. Accredited investors interested in companies that have not yet gone public can review UpMarket's current pre-IPO offerings.
Olive is no longer an independent operating company, so its shares are not available to buy. This page is kept for its historical funding and valuation data. UpMarket does not offer Olive shares.
In a pre-IPO transaction, accredited investors purchase shares from existing shareholders (such as employees, early investors, or other holders) through secondary market platforms. The company itself does not issue new shares in these transactions. UpMarket facilitates these trades as a FINRA-registered broker-dealer, handling compliance, documentation, and settlement on behalf of both parties.
Olive sold its assets to Waystar and Humata Health in October 2023. What former shareholders received was set by the terms of that sale.
UpMarket does not offer Olive shares. The minimum for most pre-IPO offerings on UpMarket is $50,000.
Olive's last valuation was set by the sale of its assets to Waystar and Humata Health. The figures on this page show its valuation history before the sale.
Olive is a private healthcare automation company that uses software and AI to reduce administrative work for hospitals, health systems, and payers. It sold its assets to Waystar and Humata Health in Oct 2023. UpMarket does not offer its shares.